Blog of Signaling Pathways

Effects of oral administration of methazolamide on intraocular pressure

May 22 2013

In vitro characterization of the erythrocyte distribution of methazolamide: a model of erythrocyte transport and binding kinetics >Read the Full Post

( 0 )Comments | ( 12 )Read

Rucaparib is a PARP inhibitor being investigated as a potential anticancer agent

May 20 2013

Rucaparib also reduces the migration of some cancer and normal cells in culture.It can be taken orally in tablet form. >Read the Full Post

( 0 )Comments | ( 15 )Read

Motesanib is an experimental drug candidate

May 16 2013

Motesanib Diphosphate has broad activity against the human VEGFR family, and displays >1000 selectivity against EGFR, Src, and p38 kinase. >Read the Full Post

( 0 )Comments | ( 21 )Read

Ouabain is found in the ripe seeds of African plants

May 14 2013

It is well understood that the classical mechanism of action of ouabain involves its binding to and inhibition of the plasma membrane Na+/K+-ATPase (sodium pump) especially at the higher concentrations attainable in vitro or with intravenous dosage. >Read the Full Post

( 0 )Comments | ( 30 )Read

MK 801 has a great deal of potential to be used in research in creating animal models of schizophrenia

May 10 2013

MK-801 has a great deal of potential to be used in research in creating animal models of schizophrenia. Unlike dopaminergic agonists, which mimic only the positive symptoms of schizophrenia, a single injection of MK801 was successful in modelling both the positive and negative symptoms of schizophrenia. >Read the Full Post

( 0 )Comments | ( 35 )Read

Selumetinib is a drug being investigated for the treatment of various types of cancer

May 08 2013

AZD6244 also inhibits the growth of primary HCC cells through inhibition of ERK1/2 and p90RSK phosphorylation, accompanied with elevation of the cleavage of caspase-3 and caspase-7, and cleaved poly(ADP)ribose polymerase. >Read the Full Post

( 0 )Comments | ( 42 )Read

Taxol is a mitotic inhibitor used in cancer chemotherapy

May 06 2013

Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. >Read the Full Post

( 0 )Comments | ( 34 )Read

LY2484595 is one of two CETP inhibitors currently being evaluated

May 02 2013

LY2484595 results in 98.4%, 98.6%, and 18.4% inhibition of CETP activity at 4 hours, 8 hours and 24 hours post dose respectively in human ApoAI and CETP double transgenic mice. >Read the Full Post

( 0 )Comments | ( 41 )Read

Tubastatin A was substantially more selective than the known HDAC6 inhibitor

Apr 28 2013

Tubastatin A is substantially selective for all 11 HDAC isoforms and maintains over 1000-fold selectivity against all isoforms excluding HDAC8, where it has approximately 57-fold selectivity. >Read the Full Post

( 0 )Comments | ( 71 )Read

SP600125 is supplied as a lyophilized powder

Apr 26 2013

SP600125 is originally characterized as a selective ATP-competitive inhibitor of c-Jun N-terminal kinase JNK. In Jurkat T cells, SP600125 inhibits the phosphorylation of c-Jun with IC50 of 5 μM to 10 μM. >Read the Full Post

( 0 )Comments | ( 60 )Read

Contact or follow me!

  • Subscribe by Email

Archives